The inherited bone marrow failure syndromes

Pediatric Clinics of North America

Volumn 60, Issue 6, 2013, Pages 1291-1310

  Chirnomas, S Deborah ^a   Kupfer, Gary M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow failure; Cancer susceptibility; Diamond Blackfan anemia; DNA repair; Dyseratosis congenita; Fanconi anemia; Ribosomopathies; Shwachman Diamond

Indexed keywords

ANDROGEN; RIBOSOME PROTEIN; RIBOSOME RNA;

AMEGAKARYOCYTIC THROMBOCYTOPENIA; BLACKFAN DIAMOND ANEMIA; BONE MARROW DEPRESSION; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER SUSCEPTIBILITY; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILITY; CONGENITAL DYSERYTHROPOIETIC ANEMIA; CYTOGENETICS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPAIR; DRUG MECHANISM; DYSKERATOSIS CONGENITA; FANCONI ANEMIA; FLOW CYTOMETRY; GENE; GENE MUTATION; GENOTYPING TECHNIQUE; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR PATHOLOGY; NONHUMAN; PANCYTOPENIA; PEARSON SYNDROME; RETICULAR DYSGENESIS; REVIEW; RIBOSOMOPATHY; SBDS GENE; SHWACHMAN SYNDROME; SOLID TUMOR; TELOMERE HOMEOSTASIS; THROMBOCYTOPENIA;

BONE MARROW FAILURE; CANCER SUSCEPTIBILITY; DIAMOND-BLACKFAN ANEMIA; DNA REPAIR; DYSERATOSIS CONGENITA; FANCONI ANEMIA; RIBOSOMOPATHIES; SHWACHMAN-DIAMOND;

BONE MARROW; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; RIBOSOMES;

EID: 84887538621     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2013.09.007     Document Type: Review

References (155)

1. Narla A., Ebert B.L. Ribosomopathies: human disorders of ribosome dysfunction. Blood 2010, 115(16):3196-3205.
2. Danilova N., Sakamoto K.M., Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood 2008, 112(13):5228-5237.
3. McGowan K.A., Li J.Z., Park C.Y., et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet 2008, 40(8):963-970.
4. Burwick N., Shimamura A., Liu J.M. Non-Diamond Blackfan anemia disorders of ribosome function: Shwachman Diamond syndrome and 5q- syndrome. Semin Hematol 2011, 48(2):136-143.
5. Diamond L.K. Congenital hypoplastic anemia: Diamond-Blackfan syndrome. Historical and clinical aspects. Blood Cells 1978, 4(1-2):209-213.
6. Alter B.P., Nathan D.G. Red cell aplasia in children. Arch Dis Child 1979, 54(4):263-267.
7. Slayton W.B., Schibler K.R. Congenital bone marrow failure syndromes associated with protean developmental defects and leukemia. Clin Perinatol 2000, 27(3):543-558.
8. Willig T.N., Gazda H., Sieff C.A. Diamond-Blackfan anemia. Curr Opin Hematol 2000, 7(2):85-94.
9. Willig T.N., Ball S.E., Tchernia G. Current concepts and issues in Diamond-Blackfan anemia. Curr Opin Hematol 1998, 5(2):109-115.
10. Gray P.H. Pure red-cell aplasia. Occurrence in three generations. Med J Aust 1982, 1(12):519-521.
11. Gojic V., van't Veer-Korthof E.T., Bosch L.J., et al. Congenital hypoplastic anemia: another example of autosomal dominant transmission. Am J Med Genet 1994, 50(1):87-89.
12. Viskochil D.H., Carey J.C., Glader B.E., et al. Congenital hypoplastic (Diamond-Blackfan) anemia in seven members of one kindred. Am J Med Genet 1990, 35(2):251-256.
13. Alter B.P. Thumbs and anemia. Pediatrics 1978, 62(4):613-614.
14. Sieff C.A., Nisbet-Brown E., Nathan D.G. Congenital bone marrow failure syndromes. Br J Haematol 2000, 111(1):30-42.
15. Krijanovski O.I., Sieff C.A. Diamond-Blackfan anemia. Hematol Oncol Clin North Am 1997, 11(6):1061-1077.
16. Hammond D., Shore N., Movassaghi N. Production, utilization and excretion of erythropoietin. I. Chronic anemias. II. Aplastic crisis. 3. Erythropoietic effects of normal plasma. Ann N Y Acad Sci 1968, 149(1):516-527.
17. Alter B.P. Fetal erythropoiesis in stress hematopoiesis. Exp Hematol 1979, 7(Suppl 5):200-209.
18. Buchanan G.R., Alter B.P., Holtkamp C.A., et al. Platelet number and function in Diamond-Blackfan anemia. Pediatrics 1981, 68(2):238-241.
19. Giri N., Kang E., Tisdale J.F., et al. Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia. BrJ Haematol 2000, 108(1):167-175.
20. Alter B., Young N. The bone marrow failure syndromes. Hematology of infancy and childhood 1998, 237-335. WB Saunders, Philadelphia. D. Nathan, S. Orkin (Eds.).
21. Sjolin S., Wranne L. Treatment of congenital hypoplastic anemia with prednisone. Scand J Haematol 1970, 7(1):63-72.
22. Vlachos A., Muir E. How I treat Diamond-Blackfan anemia. Blood 2010, 116(19):3715-3723.
23. Greinix H.T., Storb R., Sanders J.E., et al. Long-term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond-Blackfan syndrome). Br J Haematol 1993, 84(3):515-520.
24. Mugishima H., Gale R.P., Rowlings P.A., et al. Bone marrow transplantation for Diamond-Blackfan anemia. Bone Marrow Transplant 1995, 15(1):55-58.
25. Niemeyer C.M., Baumgarten E., Holldack J., et al. Treatment trial with recombinant human erythropoietin in children with congenital hypoplastic anemia. Contrib Nephrol 1991, 88:276-280.
26. Gillio A.P., Faulkner L.B., Alter B.P., et al. Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3. Blood 1993, 82(3):744-751.
27. Dunbar C.E., Smith D.A., Kimball J., et al. Treatment of Diamond-Blackfan anaemia with haematopoietic growth factors, granulocyte-macrophage colony stimulating factor and interleukin 3: sustained remissions following IL-3. Br J Haematol 1991, 79(2):316-321.
28. Janov A.J., Leong T., Nathan D.G., et al. Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore) 1996, 75(2):77-78.
29. Basso G., Cocito M.G., Rebuffi L., et al. Congenital hypoplastic anaemia developed in acute megakarioblastic leukaemia. A case report. Helv Paediatr Acta 1981, 36(3):267-270.
30. Krishnan E.U., Wegner K., Garg S.K. Congenital hypoplastic anemia terminating in acute promyelocytic leukemia. Pediatrics 1978, 61(6):898-901.
31. D'Oelsnitz M., Vincent L., De Swarte M., et al. Proceedings: acute lymphoblastic leukemia following treatment of Blackfan-Diamond's disease. Arch Fr Pediatr 1975, 32(6):582. [in French].
32. van Dijken P.J., Verwijs W. Diamond-Blackfan anemia and malignancy. A case report and a review of the literature. Cancer 1995, 76(3):517-520.
33. Seip M. Malignant tumors in two patients with Diamond-Blackfan anemia treated with corticosteroids and androgens. Pediatr Hematol Oncol 1994, 11(4):423-426.
34. Aquino V.M., Buchanan G.R. Osteogenic sarcoma in a child with transfusion-dependent Diamond-Blackfan anemia. JPediatr Hematol Oncol 1996, 18(2):230-232.
35. Willig T.N., Draptchinskaia N., Dianzani I., et al. Mutations in ribosomal protein S19 gene and Diamond Blackfan anemia: wide variations in phenotypic expression. Blood 1999, 94(12):4294-4306.
36. Draptchinskaia N., Gustavsson P., Andersson B., et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet 1999, 21(2):169-175.
37. Landowski M., O'Donohue M.F., Buros C., et al. Novel deletion of RPL15 identified by array-comparative genomic hybridization in Diamond-Blackfan anemia. Hum Genet 2013, [Epub ahead of print].
38. Sankaran V.G., Ghazvinian R., Do R., et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. JClin Invest 2012, 122(7):2439-2443.
39. Nathan D.G., Clarke B.J., Hillman D.G., et al. Erythroid precursors in congenital hypoplastic (Diamond-Blackfan) anemia. JClin Invest 1978, 61(2):489-498.
40. Freedman M.H., Amato D., Saunders E.F. Erythroid colony growth in congenital hypoplastic anemia. JClin Invest 1976, 57(3):673-677.
41. Lipton J.M., Kudisch M., Gross R., et al. Defective erythroid progenitor differentiation system in congenital hypoplastic (Diamond-Blackfan) anemia. Blood 1986, 67(4):962-968.
42. McGuckin C.P., Ball S.E., Gordon-Smith E.C. Diamond-Blackfan anaemia: three patterns of invitro response to haemopoietic growth factors. Br J Haematol 1995, 89(3):457-464.
43. Perdahl E.B., Naprstek B.L., Wallace W.C., et al. Erythroid failure in Diamond-Blackfan anemia is characterized by apoptosis. Blood 1994, 83(3):645-650.
44. Ershler W.B., Ross J., Finlay J.L., et al. Bone-marrow microenvironment defect in congenital hypoplastic anemia. NEngl J Med 1980, 302(24):1321-1327.
45. Cui D., Li L., Lou H., et al. The ribosomal protein S26 regulates p53 activity in response to DNA damage. Oncogene 2013, [Epub ahead of print].
46. Ellis S.R. DBA, del(5q): a reciprocal relationship. Blood 2011, 118(8):2032-2033.
47. Payne E.M., Virgilio M., Narla A., et al. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway. Blood 2012, 120(11):2214-2224.
48. Drachtman R.A., Alter B.P. Dyskeratosis congenita. Dermatol Clin 1995, 13(1):33-39.
49. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000, 110(4):768-779.
50. Anil S., Beena V.T., Raji M.A., et al. Oral squamous cell carcinoma in a case of dyskeratosis congenita. Ann Dent 1994, 53(1):15-18.
51. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011, 2011:480-486.
52. Mason P.J., Bessler M. The genetics of dyskeratosis congenita. Cancer Genet 2011, 204(12):635-645.
53. Ballew B.J., Savage S.A. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol 2013, 6(3):327-337.
54. Liu J.M., Ellis S.R. Ribosomes and marrow failure: coincidental association or molecular paradigm?. Blood 2006, 107(12):4583-4588.
55. Rackley S., Pao M., Seratti G.F., et al. Neuropsychiatric conditions among patients with dyskeratosis congenita: a link with telomere biology?. Psychosomatics 2012, 53(3):230-235.
56. Pritchard S.L., Junker A.K. Positive response to granulocyte-colony-stimulating factor in dyskeratosis congenita before matched unrelated bone marrow transplantation. Am J Pediatr Hematol Oncol 1994, 16(2):186-187.
57. Oehler L., Reiter E., Friedl J., et al. Effective stimulation of neutropoiesis with rh G-CSF in dyskeratosis congenita: a case report. Ann Hematol 1994, 69(6):325-327.
58. Rocha V., Devergie A., Socie G., et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998, 103(1):243-248.
59. Knight S., Vulliamy T., Copplestone A., et al. Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol 1998, 103(4):990-996.
60. Gadalla S.M., Sales-Bonfim C., Carreras J., et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant 2013, 19(8):1238-1243.
61. Smith O.P., Hann I.M., Chessells J.M., et al. Haematological abnormalities in Shwachman-Diamond syndrome. Br J Haematol 1996, 94(2):279-284.
62. Smith O.P. Shwachman-Diamond syndrome. Semin Hematol 2002, 39(2):95-102.
63. Boocock G.R., Morrison J.A., Popovic M., et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 2003, 33(1):97-101.
64. Tulpule A., Kelley J.M., Lensch M.W., et al. Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell 2013, 12(6):727-736.
65. Burwick N., Coats S.A., Nakamura T., et al. Impaired ribosomal subunit association in Shwachman-Diamond syndrome. Blood 2012, 120(26):5143-5152.
66. Barrios N., Kirkpatrick D., Regueira O., et al. Bone marrow transplant in Shwachman Diamond syndrome. Br J Haematol 1991, 79(2):337-338.
67. Adachi N., Tsuchiya H., Nunoi H., et al. rhG-CSF for Shwachman's syndrome. Lancet 1990, 336(8723):1136.
68. Dale D.C., Bonilla M.A., Davis M.W., et al. Arandomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993, 81(10):2496-2502.
69. Makitie O., Kaitila I. Cartilage-hair hypoplasia-clinical manifestations in 108 Finnish patients. Eur J Pediatr 1993, 152(3):211-217.
70. Makitie O., Sulisalo T., de la Chapelle A., et al. Cartilage-hair hypoplasia. JMed Genet 1995, 32(1):39-43.
71. le Merrer M., Briard M.L., Chauvet M.L., et al. Autosomal recessive metaphyseal chondrodysplasia and Hirschsprung's disease. Ann Pediatr (Paris) 1991, 38(1):27-30. [in French].
72. Ridanpaa M., van Eenennaam H., Pelin K., et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 2001, 104(2):195-203.
73. Maida Y., Yasukawa M., Furuuchi M., et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 2009, 461(7261):230-235.
74. Ganapathi K.A., Shimamura A. Ribosomal dysfunction and inherited marrow failure. Br J Haematol 2008, 141(3):376-387.
75. Juvonen E., Makitie O., Makipernaa A., et al. Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia. Eur J Pediatr 1995, 154(1):30-34.
76. Virolainen M., Savilahti E., Kaitila I., et al. Cellular and humoral immunity in cartilage-hair hypoplasia. Pediatr Res 1978, 12(10):961-966.
77. Makitie O., Rajantie J., Kaitila I. Anaemia and macrocytosis-unrecognized features in cartilage-hair hypoplasia. Acta Paediatr 1992, 81(12):1026-1029.
78. Gorlin R. Cartilage-hair-hypoplasia and Hodgkin disease. Am J Med Genet 1992, 44:539.
79. Taskinen M., Jeskanen L., Karjalainen-Lindsberg M.L., et al. Combating cancer predisposition in association with idiopathic immune deficiency: a recurrent nodal and cutaneous T-cell lymphoproliferative disease in a patient with cartilage-hair hypoplasia. Clin Lymphoma Myeloma Leuk 2013, 13(1):73-76.
80. Alter B.P. Fanconi's anemia, transplantation, and cancer. Pediatr Transplant 2005, 9(Suppl 7):81-86.
81. Lowy D.R., Gillison M.L. Anew link between Fanconi anemia and human papillomavirus-associated malignancies. JNatl Cancer Inst 2003, 95(22):1648-1650.
82. Masserot C., Peffault de Latour R., Rocha V., et al. Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. Cancer 2008, 113(12):3315-3322.
83. Bagby G.C., Alter B.P. Fanconi anemia. Semin Hematol 2006, 43(3):147-156.
84. D'Andrea A.D., Dahl N., Guinan E.C., et al. Marrow failure. Hematology Am Soc Hematol Educ Program 2002, 58-72.
85. Tischkowitz M., Dokal I. Fanconi anaemia and leukaemia-clinical and molecular aspects. Br J Haematol 2004, 126(2):176-191.
86. Hirschhorn R. Invivo reversion to normal of inherited mutations in humans. JMed Genet 2003, 40(10):721-728.
87. Soulier J., Leblanc T., Larghero J., et al. Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 2005, 105(3):1329-1336.
88. Velez-Ruelas M.A., Martinez-Jaramillo G., Arana-Trejo R.M., et al. Hematopoietic changes during progression from Fanconi anemia into acute myeloid leukemia: case report and brief review of the literature. Hematology 2006, 11(5):331-334.
89. Rochowski A., Olson S.B., Alonzo T.A., et al. Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML. Pediatr Blood Cancer 2012, 59(5):922-924.
90. Mehta P.A., Ileri T., Harris R.E., et al. Chemotherapy for myeloid malignancy in children with Fanconi anemia. Pediatr Blood Cancer 2007, 48(7):668-672.
91. Scheckenbach K., Wagenmann M., Freund M., et al. Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines. Klin Padiatr 2012, 224(3):132-138.
92. Somyajit K., Subramanya S., Nagaraju G. RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer. Carcinogenesis 2010, 31(12):2031-2038.
93. Cantor S.B., Guillemette S. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. Future Oncol 2011, 7(2):253-261.
94. Coulet F., Fajac A., Colas C., et al. Germline RAD51C mutations in ovarian cancer susceptibility. Clin Genet 2013, 83(4):332-336.
95. Kobayashi H., Ohno S., Sasaki Y., et al. Hereditary breast and ovarian cancer susceptibility genes (Review). Oncol Rep 2013, [Epub ahead of print].
96. Tischkowitz M., Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 2010, 70(19):7353-7359.
97. Do K., Chen A.P. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res 2013, 19(5):977-984.
98. Meyer S., Fergusson W.D., Whetton A.D., et al. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption. Genes Chromosomes Cancer 2007, 46(4):359-372.
99. Farzin A., Davies S.M., Smith F.O., et al. Matched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: an update of the Cincinnati Children's experience. Br J Haematol 2007, 136(4):633-640.
100. Pasquini R., Carreras J., Pasquini M.C., et al. HLA-matched sibling hematopoietic stem cell transplantation for Fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. Biol Blood Marrow Transplant 2008, 14(10):1141-1147.
101. Gluckman E., Wagner J.E. Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome. Bone Marrow Transplant 2008, 41(2):127-132.
102. Chaudhury S., Auerbach A.D., Kernan N.A., et al. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol 2008, 140(6):644-655.
103. Balci Y.I., Akdemir Y., Gumruk F., et al. CD-34 selected hematopoetic stem cell transplantation from HLA identical family members for Fanconi anemia. Pediatr Blood Cancer 2008, 50(5):1065-1067.
104. Kelly P.F., Radtke S., von Kalle C., et al. Stem cell collection and gene transfer in Fanconi anemia. Mol Ther 2007, 15(1):211-219.
105. Croop J.M. Gene therapy for Fanconi anemia. Curr Hematol Rep 2003, 2(4):335-340.
106. Velazquez I., Alter B.P. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 2004, 77(3):257-267.
107. Ozenne V., Paradis V., Vullierme M.P., et al. Liver tumours in patients with Fanconi anaemia: a report of three cases. Eur J Gastroenterol Hepatol 2008, 20(10):1036-1039.
108. Bogliolo M., Schuster B., Stoepker C., et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet 2013, 92(5):800-806.
109. Kottemann M.C., Smogorzewska A. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 2013, 493(7432):356-363.
110. Green A.M., Kupfer G.M. Fanconi anemia. Hematol Oncol Clin North Am 2009, 23(2):193-214.
111. Kee Y., D'Andrea A.D. Molecular pathogenesis and clinical management of Fanconi anemia. JClin Invest 2012, 122(11):3799-3806.
112. Gordon-Smith E.C., Rutherford T.R. Fanconi anaemia-constitutional, familial aplastic anaemia. Baillieres Clin Haematol 1989, 2(1):139-152.
113. Bornman L., Baladi S., Richard M.J., et al. Differential regulation and expression of stress proteins and ferritin in human monocytes. JCell Physiol 1999, 178(1):1-8.
114. Kovacic P., Jacintho J.D. Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem 2001, 8(7):773-796.
115. Evans L.M., Davies J.S., Anderson R.A., et al. The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 2000, 142(3):254-262.
116. Memoli S., Napolitano A., d'Ischia M., et al. Diffusible melanin-related metabolites are potent inhibitors of lipid peroxidation. Biochim Biophys Acta 1997, 1346(1):61-68.
117. Wells P.G., Kim P.M., Laposa R.R., et al. Oxidative damage in chemical teratogenesis. Mutat Res 1997, 396(1-2):65-78.
118. Cumming R.C., Lightfoot J., Beard K., et al. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med 2001, 7(7):814-820.
119. Zanier R., Briot D., Dugas du Villard J.A., et al. Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation. Oncogene 2004, 23(29):5004-5013.
120. Langevin F., Crossan G.P., Rosado I.V., et al. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 2011, 475(7354):53-58.
121. Fagerlie S.R., Koretsky T., Torok-Storb B., et al. Impaired type I IFN-induced Jak/STAT signaling in FA-C cells and abnormal CD4+ Th cell subsets in Fancc-/- mice. JImmunol 2004, 173(6):3863-3870.
122. Ceccaldi R., Parmar K., Mouly E., et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 2012, 11(1):36-49.
123. Li J., Sejas D.P., Zhang X., et al. TNF-alpha induces leukemic clonal evolution exvivo in Fanconi anemia group C murine stem cells. JClin Invest 2007, 117(11):3283-3295.
124. Pang Q., Andreassen P.R. Fanconi anemia proteins and endogenous stresses. Mutat Res 2009, 668(1-2):42-53.
125. Pearson H.A., Lobel J.S., Kocoshis S.A., et al. Anew syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. JPediatr 1979, 95(6):976-984.
126. Fellman V., Kotarsky H. Mitochondrial hepatopathies in the newborn period. Semin Fetal Neonatal Med 2011, 16(4):222-228.
127. Finsterer J. Hematological manifestations of primary mitochondrial disorders. Acta Haematol 2007, 118(2):88-98.
128. Bader-Meunier B., Rotig A., Mielot F., et al. Refractory anaemia and mitochondrial cytopathy in childhood. Br J Haematol 1994, 87(2):381-385.
129. Rotig A., Cormier V., Blanche S., et al. Pearson's marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. JClin Invest 1990, 86(5):1601-1608.
130. Casademont J., Barrientos A., Cardellach F., et al. Multiple deletions of mtDNA in two brothers with sideroblastic anemia and mitochondrial myopathy and in their asymptomatic mother. Hum Mol Genet 1994, 3(11):1945-1949.
131. Cherry A.B., Gagne K.E., McLoughlin E.M., et al. Induced pluripotent stem cells with a pathological mitochondrial DNA deletion. Stem Cells 2013, 31(7):1287-1297.
132. Vaal O.D., Seynhaeve V. Reticular dysgenesia. Lancet 1959, 2:1123.
133. Bujan W., Ferster A., Azzi N., et al. Use of recombinant human granulocyte colony stimulating factor in reticular dysgenesis. Br J Haematol 1992, 81(1):128-130.
134. Bujan W., Ferster A., Sariban E., et al. Effect of recombinant human granulocyte colony-stimulating factor in reticular dysgenesis. Blood 1993, 82(5):1684.
135. Azcona C., Alzina V., Barona P., et al. Use of recombinant human granulocyte-macrophage colony stimulating factor in an infant with reticular dysgenesis. Eur J Pediatr 1994, 153(3):164-166.
136. Pannicke U., Honig M., Hess I., et al. Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. Nat Genet 2009, 41(1):101-105.
137. Levinsky R.J., Tiedeman K. Successful bone-marrow transplantation for reticular dysgenesis. Lancet 1983, 1(8326 Pt 1):671-672.
138. Roper M., Parmley R.T., Crist W.M., et al. Severe congenital leukopenia (reticular dysgenesis). Immunologic and morphologic characterizations of leukocytes. Am J Dis Child 1985, 139(8):832-835.
139. Ballmaier M., Germeshausen M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost 2011, 37(6):673-681.
140. Stoddart M.T., Connor P., Germeshausen M., et al. Congenital amegakaryocytic thrombocytopenia (CAMT) presenting as severe pancytopenia in the first month of life. Pediatr Blood Cancer 2013, 60(9):E94-E96.
141. Fadoo Z., Naqvi S.M. Acute myeloid leukemia in a patient with thrombocytopenia with absent radii syndrome. JPediatr Hematol Oncol 2002, 24(2):134-135.
142. Go R.S., Johnston K.L. Acute myelogenous leukemia in an adult with thrombocytopenia with absent radii syndrome. Eur J Haematol 2003, 70(4):246-248.
143. Iolascon A., Esposito M.R., Russo R. Clinical aspects and pathogenesis of congenital dyserythropoietic anemias: from morphology to molecular approach. Haematologica 2012, 97(12):1786-1794.
144. Wickramasinghe S.N. Congenital dyserythropoietic anaemias: clinical features, haematological morphology and new biochemical data. Blood Rev 1998, 12(3):178-200.
145. Parez N., Dommergues M., Zupan V., et al. Severe congenital dyserythropoietic anaemia type I: prenatal management, transfusion support and alpha-interferon therapy. Br J Haematol 2000, 110(2):420-423.
146. Halpern Z., Rahmani R., Levo Y. Severe hemochromatosis: the predominant clinical manifestation of congenital dyserythropoietic anemia type 2. Acta Haematol 1985, 74(3):178-180.
147. Sandstrom H., Wahlin A., Eriksson M., et al. Intravascular haemolysis and increased prevalence of myeloma and monoclonal gammopathy in congenital dyserythropoietic anaemia, type III. Eur J Haematol 1994, 52(1):42-46.
148. Wickramasinghe S.N., Wood W.G. Advances in the understanding of the congenital dyserythropoietic anaemias. Br J Haematol 2005, 131(4):431-446.
149. Vainchenker W., Breton-Gorius J., Guichard J., et al. Congenital dyserythropoietic anemia type III. Studies on erythroid differentiation of blood erythroid progenitor cells (BFUE) invitro. Exp Hematol 1980, 8(8):1057-1062.
150. Vainchenker W., Guichard J., Bouguet J., et al. Congenital dyserythropoietic anaemia type I: absence of clonal expression in the nuclear abnormalities of cultured erythroblasts. Br J Haematol 1980, 46(1):33-37.
151. Dgany O., Avidan N., Delaunay J., et al. Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1. Am J Hum Genet 2002, 71(6):1467-1474.
152. Arnaud L., Saison C., Helias V., et al. Adominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet 2010, 87(5):721-727.
153. Renella R., Roberts N.A., Brown J.M., et al. Codanin-1 mutations in congenital dyserythropoietic anemia type 1 affect HP1{alpha} localization in erythroblasts. Blood 2011, 117(25):6928-6938.
154. Schwarz K., Iolascon A., Verissimo F., et al. Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II. Nat Genet 2009, 41(8):936-940.
155. Liljeholm M., Irvine A.F., Vikberg A.L., et al. Congenital dyserythropoietic anemia type III (CDA III) is caused by a mutation in kinesin family member, KIF23. Blood 2013, 121(23):4791-4799.